Previous 10 | Next 10 |
LEXINGTON, Mass. , May 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target enrollment of mesotheliom...
LEXINGTON, Mass. , April 10, 2019 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing Qualifications Department (t...
LEXINGTON, Mass. , April 5, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 2, 2019 , the independent Compensation Committee of the Board of Directors...
The first quarter of the year has been kind to the biotechnology sector in terms of stock performance and the overarching NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ). Since the start of the year, the index has increased from 3,061.26 points to 3,550.20 points as of Thursday (April 4), wh...
Curis, Inc. (CRIS) Q4 2018 Earnings Conference Call March 26, 2019 04:30 PM ET Company Participants Bill Steinkrauss - VP, Finance Jim Dentzer - President and CEO Bob Martell - Head of R&D Conference Call Participants Adnan Butt - Guggenheim Securities Presentation ...
Curis (NASDAQ: CRIS ): Q4 GAAP EPS of -$0.18 beats by $0.03 . More news on: Curis, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LEXINGTON, Mass. , March 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2018. ...
March 26, 2019 Palm Beach, FL – March 26, 2019 – At present, medical practitioners have few options when they are presented with a patient with leukemia. The Leukemia & Lymphoma Society’s website points out that : “It’s important that your doctor ...
Curis (NASDAQ: CRIS ) +74% on selling Portion of Erivedge Royalties to Oberland Capital for up to $135.7M. More news on: Curis, Inc., The9 Limited, Avaya Holdings Corp., Stocks on the move, Read more ...
LEXINGTON, Mass. , March 25, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Manage...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...